Literature DB >> 15356088

Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies.

Francesco Latrofa1, Gregorio D Chazenbalk, Pavel Pichurin, Chun-Rong Chen, Sandra M McLachlan, Basil Rapoport.   

Abstract

We used purified recombinant TSH receptor (TSHR) antigen prepared in mammalian cells to affinity-enrich TSHR autoantibodies from Graves' patients' IgG. Autoantibody enrichment, assayed by TSH binding inhibitory activity, was 20- to 1000-fold. Thyroid-stimulating antibody activity enrichment, although more difficult to quantitate, was comparable. TSHR-autoantibody approximate affinities for the holoreceptor assessed indirectly by TSH binding inhibition were 4-27 x 10(-9) m, an underestimate because 100% TSHR autoantibody purity was not attained. Consistent with previous data for serum, highly enriched TSHR autoantibodies in three of four patients showed lambda light chain bias. However, in contrast to expectations, antigen-enriched IgG was skewed primarily toward IgG2 and IgG3, subclasses associated with polysaccharides and microorganisms, respectively. Subclass depletion studies on antigen-enriched IgG indicated that TSHR autoantibodies were predominantly IgG1 and, surprisingly, IgG4. As controls, we affinity-enriched pooled IgG from normal individuals on TSHR antigen. This enriched IgG had detectable TSH binding inhibitory activity, although with lower specific activity than, and lacking the thyroid stimulatory activity of, Graves' IgG. Moreover, these natural IgG class autoantibodies largely recognized the same conformational variation in the TSHR N-terminal region as disease-associated TSHR autoantibodies. These studies suggest that TSHR autoantibodies may arise from natural autoantibodies, possibly by class switching from cross-reacting antibodies to microorganisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356088     DOI: 10.1210/jc.2003-032068

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Serum immunoglobulin G4 levels and Graves' disease phenotype.

Authors:  Carmen Sorina Martin; Anca Elena Sirbu; Minodora Andreea Betivoiu; Suzana Florea; Carmen Gabriela Barbu; Simona Vasilica Fica
Journal:  Endocrine       Date:  2016-11-07       Impact factor: 3.633

2.  Thyroglobulin autoantibodies switch to immunoglobulin (Ig)G1 and IgG3 subclasses and preserve their restricted epitope pattern after 131I treatment for Graves' hyperthyroidism: the activity of autoimmune disease influences subclass distribution but not epitope pattern of autoantibodies.

Authors:  F Latrofa; D Ricci; L Montanelli; P Piaggi; B Mazzi; F Bianchi; F Brozzi; P Santini; E Fiore; M Marinò; M Tonacchera; P Vitti
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

3.  Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease.

Authors:  Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Endocrinol Metab       Date:  2014-09-11       Impact factor: 5.958

Review 4.  Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2013-01       Impact factor: 6.568

Review 5.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

6.  Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.

Authors:  Yumiko Mizutori; Chun-Rong Chen; Francesco Latrofa; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Endocrinol Metab       Date:  2008-12-09       Impact factor: 5.958

7.  Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Graves' disease.

Authors:  Danilo Villalta; Federica D'Aurizio; Mirella Da Re; Debora Ricci; Francesco Latrofa; Renato Tozzoli
Journal:  Auto Immun Highlights       Date:  2018-02-12

8.  Epstein-Barr Virus Lytic Reactivation Induces IgG4 Production by Host B Lymphocytes in Graves' Disease Patients and Controls: A Subset of Graves' Disease Is an IgG4-Related Disease-Like Condition.

Authors:  Keiko Nagata; Sayuri Hara; Yuji Nakayama; Katsumi Higaki; Hirotsugu Sugihara; Satoshi Kuwamoto; Michiko Matsushita; Masako Kato; Shunsuke Tanio; Kiyosuke Ishiguro; Kazuhiko Hayashi
Journal:  Viral Immunol       Date:  2018-09-17       Impact factor: 2.257

Review 9.  IgG4 as a Biomarker in Graves' Orbitopathy.

Authors:  Michał Olejarz; Ewelina Szczepanek-Parulska; Daniela Dadej; Nadia Sawicka-Gutaj; Remigiusz Domin; Marek Ruchała
Journal:  Mediators Inflamm       Date:  2021-06-10       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.